Animal Model Services Global Market – Forecast to 2025

Publishing Date : August, 2017
Report Code : HCBT0113
Price:
Single license $3,600
Site license $5,400
Global license $7,200


The animal models services global market is expected to grow at single digit CAGR to reach $962.2 million by 2025. For hundreds of years, almost every medical breakthrough in human and animal health has been the result of research using animals. Animals in research are essential for the development of new and more effective methods for diagnosis and treatment of diseases that affect both humans and animals. Animals are used to learn more about health problems, and to assure the safety of new medical treatments.

Classical pharmacological models or animal models are used as a mandatory element in preclinical (toxicological and pharmacological) studies of new drugs. Although in recent years, the replacement of animal testing and animal models with in-vitro models has been increasingly introduced into practice, according to the modern manuals of pharmaco-toxicological preclinical study, some animal studies still remain compulsory.

The animal model Services global market was estimated region wise, type of animal species and therapeutic area. This report also contains ethics and regulations, animal model alternatives and applications. Assessment of most common animal models across different therapeutic areas was included. Key developments such as collaborations, acquisitions, new launches, partnerships and expansions were reported and analyzed.

  • In depth assessment of all segments and sub segments of Animal model outsourcing global market
  • Regional analysis of Animal model services global market
  • Market dynamics for animal model service global market
  • Comparison matrix for species and applications
  • Cost analysis of different animal model services
  • Comparison matrix of animal model service providers and models in respective therapeutic areas, revenues and employee size 
  • 1     ANIMAL MODEL SERVICES GLOBAL MARKET
    • 1.1     EXECUTIVE SUMMARY
  • 2     MARKET ANALYSIS
    • 2.1     FACTORS INFLUENCING MARKET
      • 2.1.1     DRIVERS AND OPPORTUNITIES
        • 2.1.1.1     NEED FOR PRECLINICAL STUDIES FOR THE APPROVAL OF THERAPEUTICS
        • 2.1.1.2     COMPLEXITY OF BIOLOGICS MAKES ANIMAL TESTING VERY IMPORTANT FOR SAFETY DATA
        • 2.1.1.3     INCREASED INVESTMENT IN R&D BY PHARMACEUTICAL COMPANIES IS INCREASING THE OUTSOURCING
        • 2.1.1.4     GENETIC ENGINEERING ADVANCEMENTS IN THE RESENT YEARS WILL INCREASE THE USE OF ANIMAL MODELS
        • 2.1.1.5     REQUIREMENT OF NOVEL BIOLOGICS THERAPEUTICS FOR CERTAIN DISEASES
      • 2.1.2     RESTRAINTS AND THREATS
        • 2.1.2.1     HIGH COST OF ANIMAL STUDIES
        • 2.1.2.2     REQUIREMENT OF LARGE NUMBER OF ANIMALS FOR MOST STUDIES
        • 2.1.2.3     ETHICAL CONCERNS AND STRINGENT REGULATIONS
        • 2.1.2.4     THREAT FROM ALTERNATIVES
  • 3     ANIMAL MODEL SERVICES
    • 3.1     INTRODUCTION
      • 3.1.1     COMPARISON MATRIX OF ANIMAL MODELS AND APPLICATIONS
      • 3.1.2     SMALL ANIMAL MODELS
      • 3.1.3     LARGE ANIMAL MODELS
    • 3.2     ETHICS AND REGULATIONS
    • 3.3     ALTERNATIVES TO ANIMAL MODELS
    • 3.4     OVERVIEW OF APPLICATIONS OF ANIMAL MODELS
    • 3.5     MARKET SHARE ANALYSIS
    • 3.6     COMPETITIVE LANDSCAPE
    • 3.7     COMPANY DEVELOPMENTS
  • 4     COMPANY PROFILES
    • 4.1     ADVINUS THERAPEUTICS
      • 4.1.1     OVERVIEW
      • 4.1.2     FINANCIALS
      • 4.1.3     SERVICE PORTFOLIO
      • 4.1.4     KEY DEVELOPMENTS
      • 4.1.5     SWOT ANALYSIS
    • 4.2     BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
      • 4.2.1     OVERVIEW
      • 4.2.2     FINANCIALS
      • 4.2.3     SERVICE PORTFOLIO
      • 4.2.4     KEY DEVELOPMENTS
      • 4.2.5     SWOT ANALYSIS
    • 4.3     CHARLES RIVER LABORATORIES
      • 4.3.1     OVERVIEW
      • 4.3.2     FINANCIALS
      • 4.3.3     SERVICE PORTFOLIO
      • 4.3.4     KEY DEVELOPMENTS
      • 4.3.5     SWOT ANALYSIS
    • 4.4     CROWN BIOSCIENCES
      • 4.4.1     OVERVIEW
      • 4.4.2     FINANCIALS
      • 4.4.3     SERVICE PORTFOLIO
      • 4.4.4     KEY DEVELOPMENTS
      • 4.4.5     SWOT ANALYSIS
    • 4.5     ENVIGO
      • 4.5.1     OVERVIEW
      • 4.5.2     FINANCIALS
      • 4.5.3     SERVICE PORTFOLIO
      • 4.5.4     KEY DEVELOPMENTS
      • 4.5.5     SWOT ANALYSIS
    • 4.6     GENOWAY
      • 4.6.1     OVERVIEW
      • 4.6.2     FINANCIALS
      • 4.6.3     SERVICE PORTFOLIO
      • 4.6.4     KEY DEVELOPMENTS
      • 4.6.5     SWOT ANALYSIS
    • 4.7     HORIZON DISCOVERY GROUP, PLC
      • 4.7.1     OVERVIEW
      • 4.7.2     FINANCIALS
      • 4.7.3     SERVICE PORTFOLIO
      • 4.7.4     KEY DEVELOPMENTS
      • 4.7.5     SWOT ANALYSIS
    • 4.8     JACKSON LABORATORY
      • 4.8.1     OVERVIEW
      • 4.8.2     FINANCIALS
      • 4.8.3     SERVICE PORTFOLIO
      • 4.8.4     KEY DEVELOPMENTS
      • 4.8.5     SWOT ANALYSIS
    • 4.9     PHARMALEGACY BIOTECHNOLOGY
      • 4.9.1     OVERVIEW
      • 4.9.2     FINANCIALS
      • 4.9.3     SERVICE PORTFOLIO
      • 4.9.4     KEY DEVELOPMENTS
      • 4.9.5     SWOT ANALYSIS
    • 4.1     PHARMARON
      • 4.10.1     OVERVIEW
      • 4.10.2     FINANCIALS
      • 4.10.3     SERVICE PORTFOLIO
      • 4.10.4     KEY DEVELOPMENTS
      • 4.10.5     SWOT ANALYSIS
    • 4.11     PSYCHOGENICS INC
      • 4.11.1     OVERVIEW
      • 4.11.2     FINANCIALS
      • 4.11.3     SERVICE PORTFOLIO
      • 4.11.4     KEY DEVELOPMENTS
      • 4.11.5     SWOT ANALYSIS
    • 4.12     SHANGHAI MEDICILON
      • 4.12.1     OVERVIEW
      • 4.12.2     FINANCIALS
      • 4.12.3     SERVICE PORTFOLIO
      • 4.12.4     KEY DEVELOPMENTS
      • 4.12.5     SWOT ANALYSIS
    • 4.13     SOBRAN INC
      • 4.13.1     OVERVIEW
      • 4.13.2     FINANCIALS
      • 4.13.3     SERVICE PORTFOLIO
      • 4.13.4     KEY DEVELOPMENTS
      • 4.13.5     SWOT ANALYSIS
    • 4.14     SYNGENE INTERNATIONAL
      • 4.14.1     OVERVIEW
      • 4.14.2     FINANCIALS
      • 4.14.3     SERVICE PORTFOLIO
      • 4.14.4     KEY DEVELOPMENTS
      • 4.14.5     SWOT ANALYSIS
    • 4.15     TACONIC BIOSCIENCES
      • 4.15.1     OVERVIEW
      • 4.15.2     FINANCIALS
      • 4.15.3     SERVICE PORTFOLIO
      • 4.15.4     KEY DEVELOPMENTS
      • 4.15.5     SWOT ANALYSIS
    • 4.16     WUXI APPTEC
      • 4.16.1     OVERVIEW
      • 4.16.2     FINANCIALS
      • 4.16.3     SERVICE PORTFOLIO
      • 4.16.4     KEY DEVELOPMENTS
      • 4.16.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     COMPARISON MATRIX OF ANIMAL MODELS AND APPLICATIONS
      • TABLE 2     MAJOR TYPES OF GENETICALLY ENGINEERED AND TRANSPLANTATION ANIMAL MODELS
      • TABLE 3     TYPICAL PRECLINICAL ISSUES OF BIOLOGICS
      • TABLE 4     ANIMAL MODEL SERVICE GLOBAL MARKET BY REGION ($MN)
      • TABLE 5     ANIMAL MODEL SERVICE GLOBAL MARKET BY TYPE OF ANIMAL SPECIES ($MN)
      • TABLE 6     ANIMAL MODEL SERVICE GLOBAL MARKET BY APPLICATION ($MN)
      • TABLE 7     ANIMAL MODEL SERVICE COST (DEVELOPMENT OF TRANSGENIC MOUSE)
      • TABLE 8     ANIMAL MODEL SERVICE COST (BASED ON DISEASE MODELS)
      • TABLE 9     ANIMAL MODEL SERVICE COST (IMAGING SERVICE COST BY AN ACADEMIC INSTITUTION)
      • TABLE 10     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE THERAPEUTIC AREAS
      • TABLE 11     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE IMMUNOLOGY/INFLAMMATION THERAPEUTIC AREAS
      • TABLE 12     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE FIBROSIS THERAPEUTIC AREAS
      • TABLE 13     COMPANY DEVELOPMENTS
      • TABLE 14     CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 15     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 16     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 17     GENOWAY: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 18     HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 19     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 20     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 21     SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 22     SYNGENE INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 23     WUXI APPTEC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MARKET DYNAMICS
      • FIGURE 2     GENOME COMPARISON
      • FIGURE 3     ANIMAL PROFILES
      • FIGURE 4     COMMON ANIMAL MODELS
      • FIGURE 5     ADVANTAGES AND DISADVANTAGES OF RODENT MODELS
      • FIGURE 6     ADVANTAGES AND DISADVANTAGES OF NHP
      • FIGURE 7     PRINCIPLES OF 3RS
      • FIGURE 8     PERCENTAGE OF ANIMALS USED IN DIFFRENT STAGES OF PHARMACUTICAL DEVELOPMENT
      • FIGURE 9     ANIMAL MODEL SERVICE GLOBAL MARKET, BY REGION ($MN)
      • FIGURE 10     ANIMAL MODEL SERVICE GLOBAL MARKET, BY TYPE OF ANIMAL SPECIES ($MN, %)
      • FIGURE 11     ANIMAL MODEL SERVICE GLOBAL MARKET, BY APPLICATION, ($MN, %)
      • FIGURE 12     ANIMAL MODEL SERVICE GLOBAL MARKET SHARE (%)
      • FIGURE 13     COMPANY DEVELOPMENTS
      • FIGURE 14     SWOT: ADVINUS THERAPEUTICS
      • FIGURE 15     SWOT: BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
      • FIGURE 16     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 17     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 18     SWOT: CROWN BIOSCIENCES
      • FIGURE 19     SWOT: ENVIGO
      • FIGURE 20     OVERVIEW: GENOWAY
      • FIGURE 21     SWOT: GENOWAY
      • FIGURE 22     OVERVIEW: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 23     SWOT: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 24     SWOT: JACKSON LABORATORY
      • FIGURE 25     SWOT: PHARMALEGACY
      • FIGURE 26     SWOT: PHARMARON
      • FIGURE 27     SWOT: PSYCOGENICS INC
      • FIGURE 28     SWOT: SHANGHAI MEDICILON
      • FIGURE 29     SWOT: SOBRAN BIOSCIENCES
      • FIGURE 30     OVERVIEW: SYNGENE INTERNATIONAL
      • FIGURE 31     SWOT: SYNGENE INTERNATIONAL
      • FIGURE 32     SWOT: TACONIC BIOSCIENCES
      • FIGURE 33     SWOT: WUXI APPTEC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ADVINUS THERAPEUTICS LTD.
      • 2     AMERICAN PRECLINICAL SERVICES
      • 3     AMPLIA PHARMATEK INC.
      • 4     ARAGEN BIOSCIENCES (GVK BIOSCIENCES)
      • 5     ARTIMMUNE SAS
      • 6     ATHENA DISCOVERY, INC 
      • 7     AVASTUS PRECLINICAL SERVICES
      • 8     BEIJING VITALSTAR BIOTECHNOLOGY CO. LTD.
      • 9     BIOMEOSTASIS
      • 10     BIOMERE
      • 11     BIOMODELS LLC.
      • 12     BIOSPECTIVE INC.
      • 13     BOLDER BIOPATH, INC.
      • 14     BTS RESEARCH
      • 15     BURLESON RESEARCH TECHNOLOGIES, INC.
      • 16     CARE RESEARCH, LLC
      • 17     CHARLES RIVER LABORATORIES
      • 18     CREATIVE ANIMODEL 
      • 19     CROWN BIOSCIENCE INC.
      • 20     CYAGEN BIOSCIENCES INC
      • 21     ENVIGO
      • 22     EUROFINS
      • 23     EXPLORA BIOLABS
      • 24     GATEWAY PHARMACOLOGY LABORATORIES
      • 25     GENOWAY
      • 26     HERA BIOLABS
      • 27     HORIZON DISCOVERY GROUP PLC.
      • 28     INFICURE BIO AB
      • 29     INTESTINAL BIOTECH DEVELOPMENT 
      • 30     INTOUCH BIOSOLUTIONS LLC
      • 31     INVITEK INC.
      • 32     JACKSON LABORATORY
      • 33     LABCORP (COVANCE)
      • 34     LANCASTER UNIVERSITY
      • 35     MD BIOSCIENCES INC.
      • 36     MELIOR DISCOVERY INC.
      • 37     MURIGENICS
      • 38     NEU ENCEPHARM GMBH
      • 39     NEUROSOLUTIONS LTD
      • 40     NOBLE LIFE SCIENCES
      • 41     PHARMACELSUS GMBH
      • 42     PHARMALEGACY LABORATORIES
      • 43     PHARMARON
      • 44     PHARMASEED
      • 45     PHYSIOGENEX
      • 46     POLYGENE TRANSGENETICS
      • 47     RENOVO NEURAL, INC.
      • 48     SCIQUUS ONCOLOGY
      • 49     SGS
      • 50     SMC LABORATORIES, INC.
      • 51     SOBRAN
      • 52     SRI INTERNATIONAL
      • 53     SYNGENE
      • 54     TACONIC BIOSCIENCES
      • 55     TNO
      • 56     TRANSCURE BIOSERVICES
      • 57     TRIBIOSCIENCES
      • 58     TRINITY BIOACTIVES LIMITED
      • 59     WILLIAM HARVEY RESEARCH LIMITED
      • 60     WOODLAND BIOSCIENCES
      • 61     WUXI APPTEC (HD BIOSCIENCES CO., LTD.)